Gamida Cell Ltd.

7.40-0.2500-3.27%Vol 127.56K1Y Perf 83.81%
Apr 19th, 2021 10:48 DELAYED
BID7.34 ASK7.40
Open7.71 Previous Close7.65
Pre-Market- After-Market-
 - -%  - -
Target Price
20.25 
Analyst Rating
Strong Buy 1.17
Potential %
170.00 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Market Cap- 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
31.78 
Earnings Date
20th May 2021

Today's Price Range

7.297.80

52W Range

3.8615.00

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-2.30%
1 Month
-13.36%
3 Months
-18.53%
6 Months
31.90%
1 Year
83.81%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
GMDA7.40-0.2500-3.27
AAPL134.370.21000.16
GOOG2 292.63-5.1300-0.22
MSFT258.95-1.7900-0.69
XOM56.12-0.5400-0.95
WFC44.010.17000.39
JNJ162.730.49000.30
FB303.08-3.1000-1.01
GE13.27-0.1200-0.90
JPM152.33-0.9700-0.63
Earnings HistoryEstimateReportedSurprise %
Q04 2020-0.31-0.68-119.35
Q03 2020-0.29-0.30-3.45
Q02 2020-0.26-0.37-42.31
Q01 2020-0.43-0.3127.91
Q04 2019-0.39-0.45-15.38
Q03 2019-0.37-0.3018.92
Q02 2019-0.55-0.87-58.18
Q01 2019-0.40-0.62-55.00
Earnings Per EndEstimateRevision %Trend
3/2021 QR-0.39-44.44Negative
6/2021 QR-0.43-53.57Negative
12/2021 FY-1.74-43.80Negative
12/2022 FY-1.46-16.80Negative
Next Report Date20th May 2021
Estimated EPS Next Report-0.37
Estimates Count3
EPS Growth Next 5 Years %-
Volume Overview
Volume127.56K
Shares Outstanding0
Trades Count1.07K
Dollar Volume5.51M
Avg. Volume902.10K
Avg. Weekly Volume258.83K
Avg. Monthly Volume334.24K
Avg. Quarterly Volume952.70K

Gamida Cell Ltd. (NASDAQ: GMDA) stock closed at 7.65 per share at the end of the most recent trading day (a -2.17% change compared to the prior day closing price) with a volume of 272.63K shares and market capitalization of 0.0000. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 83 people. Gamida Cell Ltd. CEO is Julian Adams.

The one-year performance of Gamida Cell Ltd. stock is 83.81%, while year-to-date (YTD) performance is -8.82%. GMDA stock has a five-year performance of %. Its 52-week range is between 3.86 and 15, which gives GMDA stock a 52-week price range ratio of 31.78%

Gamida Cell Ltd. currently has a PE ratio of -4.90, a price-to-book (PB) ratio of 4.84, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -64.84%, a ROC of -66.76% and a ROE of -108.74%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Gamida Cell Ltd., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.37 for the next earnings report. Gamida Cell Ltd.’s next earnings report date is 20th May 2021.

The consensus rating of Wall Street analysts for Gamida Cell Ltd. is Strong Buy (1.17), with a target price of $20.25, which is +170.00% compared to the current price. The earnings rating for Gamida Cell Ltd. stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Gamida Cell Ltd. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Gamida Cell Ltd. has a Sell technical analysis rating based on Technical Indicators (ADX : 14.03, ATR14 : 0.82, CCI20 : -103.91, Chaikin Money Flow : -0.15, MACD : -0.54, Money Flow Index : 49.47, ROC : -2.55, RSI : 40.82, STOCH (14,3) : 15.53, STOCH RSI : 0.41, UO : 45.31, Williams %R : -84.47), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Gamida Cell Ltd. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (83.33 %)
4 (100.00 %)
3 (100.00 %)
Moderate Buy
1 (16.67 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.17
Strong Buy
1.00
Strong Buy
1.00

Gamida Cell Ltd.

Gamida Cell Ltd is a biopharmaceutical company involved in developing advanced cell therapies with the potential to cure cancer and rare, serious hematologic diseases. The company's product includes NiCord that is a cell therapy based on NAM-expanded cord blood designed to enhance and expand the life-saving benefits of hematopoietic stem cell transplant. It is also developing GDA-201 which is innate immunotherapy of expanded natural killer cells, for the treatment of refractory non-Hodgkin lymphoma and multiple myeloma. It is developing a diverse pipeline of cell therapies using its proprietary NAM technology that has the potential to bring life-saving treatment options to patients.

CEO: Julian Adams

Telephone: +972 26595666

Address: 5 Nahum Heftsadie Street, Jerusalem 91340, , IL

Number of employees: 83

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

38%63%

Bearish Bullish

37%63%

Bearish Bullish

63%38%

News

Stocktwits